BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Sunday, March 15, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Oct. 3, 2008
View Archived Issues
Beta-cell function improved with R-1583, a novel long-acting GLP-1 analogue
Read More
Mechanism of action discovered for CGS-26303 in reduction of cerebral vasospasm
Read More
Limerick NeuroSciences changes name to Limerick BioPharma
Read More
Plethora completes European phase III trial of PSD-502 for premature ejaculation
Read More
New anticancer agents imparted in recent patents
Read More
Novel agents for rheumatoid arthritis disclosed in recent Janssen and Kyorin patents
Read More
Recent Rice University patent describes new antiinflammatory agents
Read More
Shire Limited changes name to Shire plc
Read More
FDA approves Reyataz boosted with ritonavir in HIV
Read More
Transcept submits NDA for Intermezzo for middle-of-the-night awakenings
Read More
Bioheart engages 35 U.S. heart failure centers in phase II/III MARVEL trial of MyoCell
Read More
Eurand revises guidance for anticipated approval and commercial launch of Zentase
Read More
GW Pharmaceuticals completes enrollment into phase III trial of Sativex in MS spasticity
Read More
Micromet signs definitive agreement for USD 40 million private equity placement
Read More
ALS submits NDA to FDA for cethromycin in CAP and signs agreement with Wyeth
Read More
Bayer Schering and the NUS enter agreement for preclinical cancer research
Read More
Pharmaxis submits MAA in Australia for Bronchitol in bronchiectasis
Read More
Ambrilia reports positive results for second phase III octreotide C2L study
Read More
Commercialization of Gatiflo discontinued in Japan
Read More
Merck & Co. discontinues taranabant development for obesity
Read More
Orexigen starts phase IIa OREX-003 trial in antipsychotic-associated weight gain
Read More
Pharmaleads advances its lead pain compound, PL-37, into phase I trials
Read More
Phase II/III study results reported for Arocyte for injection in Japan
Read More
Positive phase II results presented for rabies monoclonal antibody combination
Read More
R&D highlights from the UBS Global Life Sciences Conference in New York: Pharmasset
Read More
Merck & Co. identifies a novel bradykinin B1 antagonist
Read More
Motesanib plus standard chemotherapy safe and effective in metastatic colorectal cancer
Read More
